Blueprint Medicines

Blueprint Medicines develops therapies for allergy, oncology, and hematology. Its key products treat systemic mastocytosis and GIST in the US and EU.
Domain
Healthcare
Status
IPO’d/​Acquired
Acquisition Announcement Date
2025
IPO Date
2015
Stage of Initial Investment
Series C
Initial Investment Year
2014
Blueprint Portco Hover Image